研究について

病理・臨床検査科の医師は先端医療開発センター（臨床腫瘍病理部分野、バイオマーカー探索TR分野、病理・臨床検査TR分野）と併任になっており、がんの生物学的特性の理解や新規治療法開発を目指した研究に従事しています。また、新規抗がん剤開発にかかわるバイオマーカー検索やコンパニオン診断法の開発にも積極的に取り組んでおり、国際共同治験や東病院で実施される世界に先駆けたFIH （first in human） 試験における病理中央診断を担うなど、さまざまな臨床研究の推進に貢献しています。このほか、2017年に国立がん研究センター東病院が「がんゲノム医療中核拠点病院」に指定されたことに合わせて、病理組織標本を用いた次世代型シークエンサーによる遺伝子変異解析も運用が開始され、国立がん研究センター内外の部門・研究室との共同研究を推進してゆく予定です。
教育、研修に関しては、外科や内科からのローテーションや他大学からの研究生を積極的に受け入れており、検鏡の指導、カンファレンス、学会発表や論文作成など研究指導も行っています。

当センターの病理(病理臨床検査科・臨床腫瘍病理分野)はCOVID-19をきっかけとして、Webを通じた合同研究会を他拠点と定期的に開催し、交流を行っています。

研究の詳細については下記、業績をご参照ください。

合同研究発表会

• NEW 第6回　名古屋大学腫瘍病理学教室との合同研究発表会
  日時：2025年12月22日
  がん研究センター発表者：
  仲丸　空良　「腫瘍関連マクロファージ由来PDGF-BBによるCAF-肺腺癌細胞浸潤促進機構の解析」
  川井　将敬　「病理マルチインスタンス学習の理論とグリオーマ, メラノーマにおける応用」
• NEW 第5回　東京科学大学包括病理学教室・人体病理学教室との合同研究発表会
  日時：2025年2月10日
  がん研究センター発表者：
  川井　将敬　「病理画像におけるMultiple Instance Learningの理論と応用 ― グリオーマ(GLISP)とメラノーマ(MISSLE)の実例を添えて」
• NEW 第4回　東京医科歯科大学包括病理学教室・人体病理学教室との合同研究発表会
  日時：2024年9月3日
  がん研究センター発表者：
  高橋　 秀悟先生　「NSD3 amplificationを有する肺扁平上皮癌の臨床病理学的検討」
• 第5回　名古屋大学腫瘍病理学教室との合同研究発表会
  日時：2024 年12月24日(火曜日)　17：00～19：00
  場所：Teams
  がん研究センター発表者：
  井部　未宇　「薬剤耐性微小環境を構成するがん細胞とがん関連線維芽細胞の相互作用」
  加藤　洋人　「シーケンス技術を用いた液性腫瘍免疫の解析と新しいがん治療抗体の発見」
• 第4回　東京大学・国立がん研究センター（柏）、合同研究発表会
  日時：2025年8月19日　(火曜日)　17：30～19：30
  がん研究センター発表者
  坂下　信悟「病理AIと病理医の協働による医療の発展」
  土田　舜太「肺腺癌における節外浸潤：病理学的洞察と臨床的悪性度を示す組織学的指標としての意義」

業績

2026年

1. NEW Hoshi Y, Kuno H, Sakashita S, Hiyama T, Onaga R, Okano S, Enokida T, Fujisawa T, Tanaka N, Kishida T, Kuboki R, Kanemoto K, Ishii G, Asakage T, Tahara M. Significance of Preoperative Imaging-Detected Extranodal Extension in Pathological Extranodal Extension-Positive Head and Neck Squamous Cell Carcinoma Treated With Postoperative Chemoradiotherapy. Head Neck. 2026 Apr 3.
2. NEW Okamoto R, Hiroi T, Nakamura Y, Hashimoto H, Sakashita S, Sakamoto N, Ishikawa S, Cabral H, Stylianopoulos T, Tsukada Y, Ochiai A, Yano T, Ito M, Ishii G, Kojima M. Transgelin Expression in Activated Cancer-Associated Fibroblasts Regulates Stromal Contractility and Promotes Colon Cancer Progression. Cancer Med. 2026 Apr;15(4):e71789.
3. NEW Narusawa E, Ohtaki Y, Ishii G, Nakazawa S, Kawatani N, Yazawa T, Numajiri K, Yoshida Y, Nimura K, Shirabe K. Non-mucinous, enteric-type thymic adenocarcinoma: genetic analysis of a case. Gen Thorac Cardiovasc Surg Cases. 2026 Feb 2;5(1):8.
4. NEW Tsuchida S, Taki T, Nomura K, Suzuki K, Hashimoto H, Kubota S, Miyoshi T, Tane K, Matsumura Y, Samejima J, Aokage K, Wakabayashi M, Sasahara Y, Nagamine M, Sakashita S, Sakamoto N, Suzuki K, Tsuboi M, Ishii G. Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness. Br J Cancer. 2026 Feb;134(4):567-576.
5. NEW Takahashi S, Taki T, Nakamura N, Ura A, Kubota S, Miyoshi T, Tane K, Matsumura Y, Samejima J, Aokage K, Wakabayashi M, Sasahara Y, Nagamine M, Kojima M, Sakashita S, Sakamoto N, Hayashi T, Takamochi K, Suzuki K, Tsuboi M, Ishii G. Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples. J Thorac Oncol. 2026 Jan;21(1):135-149.
6. NEW Goto E, Aokage K, Nomura K, Tada M, Koike Y, Taki T, Miyoshi T, Tane K, Samejima J, Suzuki K, Ishii G, Tsuboi M. Long-term survival outcome after surgical resection of pulmonary neuroendocrine tumors. Surg Today. 2026 Jan;56(1):55-63.
7. NEW Watanabe H, Nagamine M, Shintani-Domoto Y, Kawanishi K, Ishino K, Nakamura T, Sumiyoshi S, Konishi E. Congophilic fibrillary glomerulonephritis recurrence post-renal transplant: diagnostic challenges and proteomic insights. CEN Case Rep. 2026 Jan 23;15(1):34.
8. NEW Nagamine M, Fujisawa T, Sakamoto N, Nakamura Y, Kadowaki S, Ueno M, Boku S, Komatsu Y, Oki E, Makiyama A, Nonomura N, Morizane C, Watari H, Okano S, Iwata H, Namikawa K, Hatanaka Y, Hatanaka KC, Taguchi K, Spetzler D, Radovich M, Magee D, Yoshino T, Oberley M, Kuwata T. HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry. JCO Precis Oncol. 2026 Jan;10:e2500413.
9. NEW Takashima H, Tsumura R, Koga Y, Anzai T, Yin X, Sato N, Shigekawa Y, Kanayama Y, Nambu A, Usuda S, Haba H, Sakashita S, Inaki A, Manabe S, Yasunaga M. Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy. Mol Pharm. 2026 Apr 6;23(4):2422-2435.
10. NEW Kawazu M, Taguchi A, Yoshida E, Yoshida H, Uno M, Inoue S, Yamamoto Y, Sakashita S, Ueno T, Nakamura Y, Lin J, Kojima S, Kawase K, Ishizaka A, Miyata S, Kojima M, Ikemura M, Sone K, Ishikawa M, Kato T, Mano H, Terao Y, Oda K. Genomic and transcriptomic analysis of high-grade endometrial carcinoma reveals biological heterogeneity and molecular classification challenges. Cancer Res Commun. 2026 Mar 30. Online ahead of print.
11. NEW Harada K, Nomura Y, Komura D, Ishikawa S, Sakashita S. Label Noise in Pathological Segmentation Is Overlooked, Leading to Potential Overestimation of Artificial Intelligence. Cancer Sci. 2026 Mar;117(3):852-863.
12. NEW Onaga R, Enokida T, Tomioka T, Sakashita S, Sato M, Tanaka N, Hoshi Y, Kishida T, Kuboki R, Fujisawa T, Okano S, Matsuura K, Tahara M. Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma. Auris Nasus Larynx. 2026 Feb;53(1):7-12.
13. NEW Sugawara K, Sakashita S, Fukuda T, Murakami C, Oka D, Amori G, Baba Y, Kanda H, Motoi N. Impacts of Mitochondrial Status After Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma Patients. Cancer Sci. 2026 Feb;117(2):491-500.
14. NEW Kuno H, Hiyama T, Sasaki T, Sakashita S, Onaga R, Tomioka T, Muramatsu Y, Akino N, Taguchi H, Sekiya K, Kobayashi T. Imaging-detected extranodal extension in head and neck cancer: clinical implications, diagnostic criteria, and the potential of photon-counting detector CT. Jpn J Radiol. 2026 Feb;44(2):221-241.
15. NEW Sada H, Niitsu H, Urabe Y, Nakahara H, Kochi M, Sakamoto N, Sotomaru Y, Tashiro H, Oka S, Ohdan H, Fearon ER, Hinoi T. Colon-restricted Pten haploinsufficiency models PI3K pathway-driven invasion in colorectal cancer. Cell Mol Gastroenterol Hepatol. 2026 Mar 25:101773. Online ahead of print.
16. NEW Okuda Y, Murai J, Takashima T, Sakamoto N, Yoshimura A, Tani M, Horibe Y, Liu Y, Sassi N, Oka T, Uemura T, Yamamoto A, Yamamichi G, Ishizuya YU, Hayashi T, Yamamoto Y, Hatano K, Kawashima A, Morii E, Nonomura N, Kato T. SLFN11 Drives GM-CSF-mediated M1 Macrophage Polarization and Enhances Immunotherapy Response in Renal Cell Carcinoma. Anticancer Res. 2026 Mar;46(3):1213-1234.
17. NEW Habu T, Ushiyama S, Nakayama I, Yura M, Yoshida M, Sakamoto N, Kuwata T, Shitara K, Kinoshita T. ASO Visual Abstract: Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy? Ann Surg Oncol. 2026 Feb;33(2):1442-1443.
18. NEW Habu T, Ushiyama S, Nakayama I, Yura M, Yoshida M, Sakamoto N, Kuwata T, Shitara K, Kinoshita T. Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy?Ann Surg Oncol. 2026 Feb;33(2):1381-1390.
19. NEW Shibuki T, Yamashita R, Hashimoto T, Fujisawa T, Imai M, Yuda J, Kuwata T, Misumi T, Nakamura Y, Bando H, Kojima K, Tokioka S, Chiba I, Nakaya N, Hozawa A, Koshiba S, Fuse N, Saito S, Shimizu R, Park WY, Kinoshita K, Yoshino T. Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI). Int J Clin Oncol. 2026 Mar 6. Online ahead of print.

2025年

1. Kunigo K, Nagasawa S, Kajiya K, Sakamoto Y, Zaha S, Kuze Y, Kanai A, Nomura K, Tsuboi M, Ishii G, Motoyoshi A, Tsugawa K, Chosokabe M, Koike J, Suzuki A, Suzuki Y, Seki M. Targeted long-read methylation analysis using hybridization capture suitable for clinical specimens. Cell Rep Methods. 2025 Nov 17;5(11):101215.
2. Sasahara Y, Fumimoto S, Ohtani-Kim SJ, Tane K, Miyoshi T, Samejima J, Aokage K, Kojima M, Sakashita S, Sakamoto N, Nagamine M, Hanaoka N, Katsumata T, Tsuboi M, Ishii G, Taki T. Feasibility of Histological Grading System of Small-sized Pulmonary Adenocarcinoma Based on Frozen Section as a Predictor for Nodal Metastasis. Mod Pathol. 2025 Nov;38(11):100849.
3. Sugata K, Aokage K, Taki T, Nomura K, Wakabayashi M, Miyoshi T, Tane K, Samejima J, Sasahara Y, Nagamine M, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Ishii G. Impact of tumor cell burden beyond the elastic layer on prognosis in T2aN0M0 non-small cell lung cancer with visceral pleural invasion. Lung Cancer. 2025 Oct;208:108759.
4. Sakai SA, Oyoshi H, Nakamura M, Taki T, Nomura K, Hojo H, Hirata H, Motegi A, Nakamura Y, Zenkoh J, Aokage K, Hamada A, Kojima M, Kuwata T, Tsuchihara K, Akimoto T, Soh J, Mitsudomi T, Tsuboi M, Ishii G, Suzuki Y, Suzuki A, Yamashita R, Kageyama SI. Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13?+?T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy. Br J Cancer. 2025 Oct;133(6):795-808.
5. Terajima D, Kojima M, Sakashita S, Taki T, Kinoshita T, Ishii G, Sakamoto N. Evaluating peritoneal elastic laminal invasion to improve stratification of patients with pT3 gastric cancer. Gastric Cancer. 2025 Sep;28(5):862-871.
6. Funasaka C, Naito Y, Kubota H, Ishiguro Y, Fuse N, Wakabayashi M, Sato A, Yuda J, Ishii G, Suzuki T, Takenouchi K, Nakatsura T, Morita K, Inada Y, Tanaka M, Nakazawa Y, Yagyu S, Doi T. Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr). Front Oncol. 2025 Aug 6;15:1633324.
7. Aoki Y, Hashimoto T, Takahashi N, Okunaka M, Mishima S, Kotani D, Kawazoe A, Nakamura Y, Nakayama I, Kuboki Y, Bando H, Kojima T, Nakamura N, Sakamoto N, Ishii G, Fujisawa T, Yoshino T, Arai Y, Shibata T, Shitara K. Clinical Significance of Extrachromosomal DNA in FGFR2-Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience. JCO Precis Oncol. 2025 Aug;9:e2500033.
8. Sakai T, Udagawa H, Izumi H, Umemura S, Zenke Y, Matsumoto S, Yoh K, Tomoyuki N, Tokiko N, Taki T, Sakamoto N, Sakashita S, Kojima M, Tsuboi M, Goto K, Ishii G. Clinicopathological Characterization of Squamous Cell Lung Carcinoma Adjacent to Emphysema. Pathol Int. 2025 Jul;75(7):329-339.
9. Uematsu M, Nakajima H, Miyake H, Wakabayashi M, Funasaka C, Kondoh C, Harano K, Matsubara N, Hosono A, Naito Y, Sakamoto N, Kojima M, Onishi T, Ishii G, Mukohara T. Digitally quantified area of residual tumor after neoadjuvant chemotherapy in HER2-positive breast cancer. Breast Cancer. 2025 Jul;32(4):716-727.
10. Onaga R, Enokida T, Sakashita S, Tanaka N, Hoshi Y, Kishida T, Kuboki R, Fujisawa T, Okano S, Nishino H, Ito M, Ishii G, Ishikawa S, Tahara M. Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer. Int J Clin Oncol. 2025 Jun;30(6):1143-1151.
11. Sasaki T, Oda S, Kuno H, Hiyama T, Taki T, Takahashi S, Ishii G, Tsuboi M, Kobayashi T. Potential of spectral imaging generated by contrast-enhanced dual-energy CT for lung cancer histopathological classification - A preliminary study. Eur J Radiol Open. 2024 Dec 26;14:100628.
12. Rokugo M, Shinozaki T, Ishii R, Ito Y, Sakashita S, Ishii G, Ogawa T, Katori Y, Matsuura K, Hayashi R. Surgery for T1/2N0 Oropharyngeal Carcinoma Is a Better Treatment Option than Radiotherapy-A Long-Term Follow-Up Study from a Single Japanese High-Volume Cancer Center. Cancers (Basel). 2025 May 31;17(11):1862.
13. Harada K, Sakamoto N, Kitaoka T, Nakamura Y, Kondo R, Morisue R, Hashimoto H, Yamamoto Y, Ukai S, Maruyama R, Sakashita S, Kojima M, Tanabe K, Ohdan H, Shitara K, Kinoshita T, Ishii G, Yasui W, Ochiai A, Ishikawa S. PI3 expression predicts recurrence after chemotherapy with DNA-damaging drugs in gastric cancer. J Pathol. 2025 Apr;265(4):472-485.
14. Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E, Umemura S, Zenke Y, Matsumoto S, Yoh K, Kubota S, Aokage K, Sakamoto N, Sakashita S, Kojima M, Nagamine M, Hosomi Y, Tsuboi M, Goto K, Ishii G. Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma. JTO Clin Res Rep. 2024 Dec 18;6(3):100779.
15. Nagata H, Kinoshita T, Sakashita S, Kojima M, Taki T, Kuwata T, Yura M, Shitara K, Ishii G, Sakamoto N. Area of Residual Tumor Measurement After Preoperative Chemotherapy as an Objective and Quantitative Method for Predicting the Prognosis of Gastric Cancer: A Single-Center Retrospective Study. World J Surg. 2025 Mar;49(3):717-726.
16. Urabe A, Adachi M, Sakamoto N, Kojima M, Ishikawa S, Ishii G, Yano T, Sakashita S. Deep learning detected histological differences between invasive and non-invasive areas of early esophageal cancer. Cancer Sci. 2025 Mar;116(3):824-834.
17. Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. NETosis in pulmonary pleomorphic carcinoma. Cancer Sci. 2025 Feb;116(2):524-532.
18. Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib. J Thorac Oncol. 2025 Feb;20(2):177-193.
19. Kojima N, Nishino S, Sasahara Y, Taki T, Imada H, Miyoshi T, Watanabe SI, Ishii G, Yatabe Y, Mori T, Yoshida A. Inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion: a report of two cases and a potential relationship with clear cell stromal tumour. Histopathology. 2025 Feb;86(3):365-372.
20. Funasaka C, Kogawa T, Sakamoto N, Kusuhara S, Nakao T, Nakajima H, Kondoh C, Harano K, Matsubara N, Hosono A, Naito Y, Shimokawa M, Watanuki R, Yamashita Y, Yamauchi C, Onishi T, Ishii G, Mukohara T. The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer. Cancer Treat Res Commun. 2025;44:100941.
21. Nagamine M, Ogi H, Hirai M, Omatsu I, Moriwaki S, Shibata S, Yasukawa S, Yoriki K, Kojima M, Mori T, Itoh K, Konishi E. Low density of intratumoral M1-macrophage infiltration may correlate with worse prognosis in low-grade early-stage uterine endometrioid carcinoma. Gynecol Oncol Rep. 2025 May 10;59:101758.
22. Nakao T, Harano K, Wakabayashi M, Taki T, Watanabe R, Tanabe H, Mukohara T. Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma. Anticancer Res. 2025 Dec;45(12):5543-5555.
23. Sasaki T, Kuno H, Nomura K, Muramatsu Y, Aokage K, Samejima J, Taki T, Goto E, Wakabayashi M, Furuya H, Taguchi H, Kobayashi T. CZT-based photon-counting-detector CT with deep-learning reconstruction: image quality and diagnostic confidence for lung tumor assessment. Jpn J Radiol. 2025 Jul;43(7):1132-1144.
24. Kami S, Kojima M, Kudo M, Kamiya H, Une N, Sasahara Y, Sugimoto M, Kobayashi S, Konishi M, Gotohda N. Clinicopathological significance and prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: a single-center, retrospective study. Hum Pathol. 2025 Dec;166:105952.
25. Sasabe M, Takashima K, Sakashita S, Koga Y, Anzai T, Yang S, Saijou S, Ishikawa A, Yamaguchi T, Tanaka H, Yoda Y, Fujita T, Mitsunaga S, Yasunaga M, Yano T. Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody. Cancer Sci. 2025 Dec;116(12):3388-3402.
26. Imaoka T, Sato K, Sakashita S, Shibutani Y, Suzuki A, Kotani D, Shitara K, Tajiri K. A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular Failure. Int Heart J. 2025 May 31;66(3):511-515.
27. Minamide T, Minakata N, Yamashita R, Sakashita S, Yoda Y, Ohashi A, Aoshima M, Kobayashi S, Yano T. Oxygen saturation imaging elucidates tumor heterogeneity in gastric cancer. DEN Open. 2025 Feb 21;5(1):e70077.
28. Takei S, Kotani D, Laliotis G, Sato K, Fujiwara N, Kawazoe A, Hashimoto T, Mishima S, Nakayama I, Nakamura Y, Bando H, Kuboki Y, Sakashita S, Spickard E, George GV, Dutta P, Sharma S, Malhotra M, Sethi H, Jurdi A, Liu MC, Yoshino T, Shitara K, Kojima T, Fujita T. Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study. Ann Surg. 2025 Mar 21.
29. Sugawara K, Sakashita S, Fukuda T, Murakami C, Oka D, Amori G, Ishibashi K, Kobayashi Y, Kanda H, Motoi N. Survival Impacts of Mitochondrial Status in Esophageal Squamous Cell Carcinoma Patients. Ann Surg Oncol. 2025 Mar;32(3):1963-1972.
30. Sugawara K, Sakashita S, Motoi N. ASO Author Reflections: Clinical Relevance of Mitochondrial Status in Patients with Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2025 Mar;32(3):1987-1988.
31. Oda S, Kuno H, Fujita T, Hiyama T, Kotani D, Kadota T, Sakashita S, Kobayashi T. Clinical usefulness of four-dimensional dynamic ventilation CT for borderline resectable locally advanced esophageal cancer. Jpn J Radiol. 2025 Mar;43(3):434-444.
32. Kajiyama D, Fujiwara N, Shigeno T, Sato K, Yamaguchi M, Sakashita S, Daiko H, Fujita T. Impact of Lymphatic and Venous Invasion Patterns on Postoperative Prognosis and Distant Metastasis in Esophageal Squamous Cell Carcinoma After Preoperative Chemotherapy. Ann Surg Oncol. 2025 Feb;32(2):860-871.
33. Ushiyama S, Habu T, Nakayama I, Yoshida M, Sakamoto N, Kawazoe A, Yamamoto K, Okemoto D, Matsubara Y, Seguchi K, Ogura T, Okazaki U, Miyashita Y, Kobayashi A, Hashimoto T, Mishima S, Kotani D, Kuboki Y, Bando H, Kojima T, Sato K, Fujita T, Shimizu Y, Yura M, Kinoshita T, Shitara K. Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients. JCO Oncol Pract. 2025 Dec 19:OP2500705.
34. Carstens EJ, Takahashi K, Sakamoto N, De Vizio M, Morgado M, Nikkhoi SK, Mangipudi A, Nguyen CH, Weltzin T, Nakayama I, Lv Q, Zeng J, Nie C, Deng C, Wang X, Liu L, Klempner SJ, Ramasubramanian A, Nowak JA, Aguirre AJ, Shitara K, Smith EL. Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat Commun. 2025 Nov 1;16(1):9651.
35. Zhang F, Nakayama I, Sakamoto N, Okemoto D, Jubashi A, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Kuwata T, Shitara K. Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ?1 metastatic gastric/gastroesophageal junction cancer. Ther Adv Med Oncol. 2025 Sep 20;17:17588359251369042.
36. Jubashi A, Nakayama I, Sakamoto N, Takei S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Kuwata T, Sato K, Fujita T, Yoshida M, Yura M, Kinoshita T, Shitara K. Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors. Ther Adv Med Oncol. 2025 Sep 20;17:17588359251369042.
37. Hashimoto T, Iida N, Nakamura Y, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Ogata T, Takahashi N, Okano N, Nishina T, Sakamoto N, Kuwata T, Yamashita R, Shibuki T, Imai M, Fujisawa T, Bando H, Shitara K, Yoshino T. Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study. Cancer Sci. 2025 Aug;116(8):2218-2231.
38. Tomi Y, Kinoshita T, Yura M, Sakamoto N, Fujita T, Tokunaga M, Kinugasa Y. Accuracy of the preoperative estimation of esophageal invasion length of adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement. Surg Today. 2025 Jun;55(6):768-777.
39. Murano T, Chung KY, Tang YC, Kano Y, Takeuchi K, Sakamoto N, Kuwata T, Gao Y, Cheong JK, Cheng H, Zhou L, Yano T. Novel and Effective Blood-Based miRNA Diagnostic Panel for Gastric Cancer: A Pilot Study in a Japanese Population. Cancer Med. 2025 Apr;14(8):e70790.
40. Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Miyaaki H, Nakao K, Shitara K. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. Gastric Cancer. 2025 Jan;28(1):63-73.
41. Luchini C, Matkowskyj KA, Kuwata T, Longacre TA, Schirmacher P, Takamatsu M, Ruschoff J, Fassan M. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Virchows Arch. 2025 Sep;487(3):487-499.
42. Abe H, Kuwata T, Kushima R, Ushiku T. Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan. Gastric Cancer. 2025 Mar;28(2):294-300.
43. Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Sawada K, Sato A, Kuwata T, Yamashita R, Fujisawa T, Bando H, Ock CY, Fujii S, Yoshino T. Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial. JCO Precis Oncol. 2025 Jan;9:e2400385.